Sai Sun Ho, MD
Internal Medicine · San Francisco, CANPI 1710952957
Payments from drug & device makers
Across 931 payments — averaging $32.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Johnson & Johnson$4K
- Gilead$3K
- Boehringer Ingelheim$3K
- GSK$2K
- Lilly USA, LLC$2K
- plus $11K from 33 others
What the payments were for
- Consulting fees$1,5405%
- Speaking & faculty fees$150%
- Food & beverage$28,92794%
- Education$1891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,672 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 320 | $398,320 |
| FarxigaDapagliflozin Propanediol | 258 | $304,523 |
| RybelsusSemaglutide | 141 | $251,406 |
| VemlidyTenofovir Alafenamide | 134 | $208,609 |
| KerendiaFinerenone | 108 | $142,662 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 129 | $131,373 |
| LinzessLinaclotide | 119 | $130,803 |
| EliquisApixaban | 104 | $129,778 |
| XareltoRivaroxaban | 109 | $112,161 |
| MounjaroTirzepatide | 72 | $102,511 |
| CreonLipase/Protease/Amylase | 28 | $88,297 |
| OzempicSemaglutide | 55 | $82,022 |
| TrulicityDulaglutide | 54 | $81,278 |
| MyrbetriqMirabegron | 54 | $67,946 |
| ProliaDenosumab | 35 | $57,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Combivent Respimat, Glyxambi | $3,025 | $496,153415 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $4,884 | $351,899303 claims |
| Novo NordiskRybelsus, Ozempic | $2,403 | $333,428196 claims |
| AbbVieLinzess, Creon | $653 | $219,099147 claims |
| GileadVemlidy | $3,035 | $208,609134 claims |
| Lilly USA, LLCMounjaro, Trulicity | $2,437 | $183,788126 claims |
| BayerKerendia | $1,337 | $142,662108 claims |
| GSKTrelegy Ellipta | $2,446 | $131,373129 claims |
| PfizerEliquis | $569 | $129,778104 claims |
| Johnson & JohnsonXarelto | $3,683 | $112,161109 claims |
| Astellas Pharma US IncMyrbetriq | $355 | $67,94654 claims |
| AmgenProlia | $579 | $57,94235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Nina ShahSan Francisco$5.4M
- Katy TsaiSan Francisco$3.8M
- Riley BoveSan Francisco$3.6M
- Jacob LalezariSan Francisco$3.3M
- Flavio VincentiSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.